Biotech Boom: Is Hong Kong’s Innovative Drug Sector Entering a “Golden Era”?

Hong Kong’s biotech stocks are suddenly back in the limelight — and this time, the momentum looks real. Share prices are skyrocketing, with a wave of doubling stocks igniting explosive enthusiasm across the market. The Yinhua CNI HK Connect Innovative Drug ETF (159567.SZ) jumped another 3.63% on June 4, pushing its year-to-date gain to an eye-popping +49.32%, making it one of the top-performing ETFs in China’s market.

As of June 4, the biopharma sector leads both A-shares and H-shares in terms of doubling stocks. In Hong Kong alone, 21 innovative drug stocks have risen over 100% in 2025, with 6 of them more than doubling and nearly 10 more hot on their heels. The bullishness is visible across the board — from pre-revenue R&D firms to large-cap players with approved drugs.

ASCO 2025: The Spark That Lit the Fire

Much of this rally was turbocharged by the 2025 ASCO Annual Meeting (May 30–June 3), the world’s most prestigious oncology conference. Chinese biotech firms showed up strong, earning global recognition.

As of June 4, 2025:

Innovent Biologics (01801.HK) surged 14.14%, hitting multi-year highs after presenting data on its novel bispecific antibody IBI363, which targets PD-1 and IL-2. The therapy showed promising efficacy in late-stage non-small cell lung cancer (NSCLC). It’s already received two Fast Track designations from the FDA and two Breakthrough Therapy designations from China’s NMPA.

China Antibody-B (03681.HK) went parabolic, soaring 42.5% — its share price doubling in just four trading days following positive immunotherapy data.

Other names like Hua Medicine-B (02552.HK), Zai Lab (ZLAB.US), and TigerMed (03347.HK) also recorded strong post-ASCO gains.

The ASCO spillover effect reached A-shares as well:

Lepu Medical (300003.SZ) rose 18.45%,
Jiuzhitang (000989.SZ) and Wanbangde (002082.SZ) both hit their daily limit-up.

Top-tier names including Hengrui, BeiGene, Akeso, and Hansoh Pharma all released encouraging trial updates at the conference — helping restore confidence in China's global R&D capabilities.

Licensing Boom: $36.9 Billion in Q1 Deals

Behind the scenes, licensing activity has exploded. In just Q1 2025, Chinese biotechs signed 41 licensing-out deals worth $36.9 billion — almost equal to the entire 2023 full-year total.

3SBio (01530.HK) and subsidiaries inked a $6 billion global licensing deal with Pfizer ($PFE) — one of the largest ever for a Chinese firm.
Hansoh Pharma (03692.HK) granted global rights (excluding Greater China) of its GLP-1/GIP candidate HS-20094 to Regeneron, in a deal worth up to $1.93 billion plus royalties.

Others like Hengrui, Livzon, InnoCare, Innovent, Simcere, and CSPC also landed billion-dollar partnerships — boosting investor confidence and lifting share prices across the sector.

Regulatory Tailwinds Strengthen

On May 29, China’s NMPA approved 11 new innovative drugs, including 9 developed domestically. These cover oncology, autoimmune disorders, metabolic diseases, and rare diseases — demonstrating the country’s maturing innovation pipeline.

From January to May 2025, 53 new drugs have been greenlit, 30 of which are homegrown. This marks a significant leap in local R&D capabilities and hints at faster regulatory pathways.

Institutions Are Turning Bullish

Institutional investors are now positioning biotech as a core investment theme for 2025.

Guotai Junan Securities believes that the sector is entering a "valuation rerating cycle," especially for firms with products nearing national reimbursement negotiations. In a June 3 report, analyst Chen Li wrote that biotech valuations still have "room for compression recovery" as clinical results improve and capital inflows accelerate.
GF Securities’ Zhang Shuo emphasized that globally competitive Chinese biotech firms with increasing licensing revenues are “undergoing long-term re-pricing.” She sees the licensing-out model as China’s answer to global expansion, making the sector more investable for global funds.
According to Wind data, public mutual funds increased their biotech holdings by 6.37 percentage points in Q1 2025, signaling a broad reallocation toward innovative drugmakers.

Even the CXO segment (Contract Research/Manufacturing) is bouncing back after taking a hit from the U.S. biosecurity bill scare in 2024. With fundamentals stabilizing and demand for cost-effective R&D services rebounding, companies like WuXi AppTec (02359.HK) and Pharmaron (03759.HK) are seeing order growth accelerate.

Final Thoughts: A “Golden Era” Emerging?

All signs point to a new chapter for Hong Kong’s innovative drug sector — one driven by cutting-edge science, global partnerships, and increasing regulatory and institutional support.

If this momentum continues, 2025 might just be remembered as the year Hong Kong’s biotech sector entered its “golden era.” For investors looking to participate without picking individual stocks, ETFs like 159567.SZ offer a lower-risk, diversified way to ride the wave.

#china #Biotech